Ortin Laboratories Limited (ORTINLAABS) Fair Value & Analysis

Healthcare · IN · Market cap ₹524M

Below-average quality, screening 107% undervalued on our models.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The model range is unusually wide (₹10.31 to ₹44.75). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• Solid quality (45/100) at a price below fair value, the discount is the argument here, not the business quality.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.

How to read this chart

60‑month range ₹9.98 – ₹68.02 · fair‑value band ₹10.31 – ₹44.75 · the ₹14.81 price screens below the ₹30.65 fair value. Dashed = 300-day average. As of Aug 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Ortin Laboratories Limited (ORTINLAABS) currently trades at ₹14.81, while our model-based Fair Value estimate is ₹30.65, implying the stock looks roughly 107.0% undervalued today. The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Ortin Laboratories Limited generated revenue of ₹2.4B at a net margin of -0.3%. Revenue grew 94.0% year over year. Fundamentals as of Aug 22, 2026

Our scenario range runs from ₹10.31 (bear case) to ₹44.75 (bull case); at ₹14.81, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 32% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -40% fair-value upside, at 107%, ORTINLAABS screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (₹35.34) versus Growth DCF (₹0.0500). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Ortin Laboratories Limited manufactures and sells pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders.

Full company description

Ortin Laboratories Limited manufactures and sells pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders. It provides formulations, such as anti diabetics, anti allergics, sedatives and tranquilisers, anti helmenthetics, analgesics and antipyretics, anti biotics-quinolones, anti biotic-pencillins, cephalosporins, and macrolides; and anti anginal and cardio vascular, and antifungal products. The company's formulations also include chemo therapeutics, antacids and anti ulcerants, anti spasmodics, calcium preparations, iron preparations, anti arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti retroviral products. In addition, it provides active pharmaceutical ingredient (API) intermediates comprising anti retro virals, anti diabetics, analgesics and antipyretics, anti biotics, antifungals, antacids and anti ulcerants, and anti malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company offers services in the areas of process development, process characterization, analytical research and development, assay development, and product characterization; and diagnostic services, including development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; and operates as a merchant exporter of pharmaceutical finished formulations. Ortin Laboratories Limited was founded in 1986 and is based in Hyderabad, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2017 – FY2020 · reported fiscal years

Ortin Laboratories Limited reported revenue of ₹2.0B in FY2020 versus ₹619M in FY2017, a compound +46.9%/yr. Reported net income was −₹5.6M in FY2020.

Watch ORTINLAABS: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 639 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.